United Therapeutics Corporation Submits Resubmitted New Drug Application for Tyvaso DPI

Strategic Insights -

United Therapeutics Corporation has filed a Form 8-K with the Securities and Exchange Commission on December 27, 2021, announcing the resubmission of its new drug application (NDA) for Tyvaso DPI, a trademark of the company. This follows the receipt of a Complete Response from the U.S. Food and Drug Administration (FDA) on October 18, 2021, regarding the initial NDA submission. The Company's move to resubmit the NDA indicates a continued commitment to bringing Tyvaso DPI to market.

Key Takeaways:

  • United Therapeutics Corporation has resubmitted its new drug application (NDA) for Tyvaso DPI to the FDA after receiving a Complete Response on October 18, 2021.
  • The resubmission of the NDA marks a significant step forward in the development process for Tyvaso DPI, a treatment for pulmonary arterial hypertension (PAH).
  • United Therapeutics Corporation issued a press release on October 18, 2021, disclosing the receipt of the Complete Response from the FDA regarding the initial NDA submission.
  • Tyvaso DPI is a trademark of United Therapeutics Corporation.

Statistics:

  • December 27, 2021: Date on which United Therapeutics Corporation filed the Form 8-K with the SEC.
  • October 18, 2021: Date on which the Company received a Complete Response from the FDA regarding the initial NDA submission.
  • 10/18/2021: Date of issuance of the press release disclosing the receipt of the Complete Response from the FDA.

Sources:

  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT
  • United Therapeutics Corporation, Form 8-K filing, December 27, 2021.